Etoposide with Carboplatin or Cisplatin + Durvalumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small-Cell Lung Cancer
Conditions
Extensive-Stage Small-Cell Lung Cancer
Trial Timeline
Jan 1, 2022 → Feb 28, 2028
NCT ID
NCT05796089About Etoposide with Carboplatin or Cisplatin + Durvalumab
Etoposide with Carboplatin or Cisplatin + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Extensive-Stage Small-Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05796089. Target conditions include Extensive-Stage Small-Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05796089 | Phase 2 | Active |
Competing Products
20 competing products in Extensive-Stage Small-Cell Lung Cancer